Aditya Bardia, MD, MPH

Articles

HR+ Metastatic Breast Cancer: Molecular Profiling and 1L Treatment Approaches

February 23rd 2023

Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.

Expert Perspectives on Defining HER2-Low Breast Cancer

February 21st 2023

Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.

Overview on Treatment Options for HER2+ Breast Cancer

February 21st 2023

Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.

How Clinical Trials Inform Treatment Selection in Early-Stage HR+ Breast Cancer

February 16th 2023

A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.

Early-Stage HR+ Breast Cancer: Ki67 and the monarchE Trial

February 16th 2023

Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.

How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer

February 9th 2023

A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.

Best Practices for Molecular Testing in Early-Stage Breast Cancer

February 9th 2023

Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.

Dr. Bardia on the FDA Approval of Sacituzumab Govitecan in HR+/HER2– Metastatic Breast Cancer

February 8th 2023

Aditya Bardia, MD, MPH, discusses the significance of the FDA approval of sacituzumab govitecan in patients with pretreated hormone receptor–positive, HER2-negative metastatic breast cancer and key data from the phase 3 TROPiCS-02 trial.

Dr. Bardia on the Ongoing Investigation of Oral SERDs in ER+/HER2- Breast Cancer

December 19th 2022

Aditya Bardia, MD, MPH, discusses the investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Dr. Bardia on Elacestrant in ER+/HER2– Metastatic Breast Cancer

December 8th 2022

Aditya Bardia, MD, MPH, discusses the use of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Future Treatment Strategies for Triple-Negative Breast Cancer

September 19th 2022

Closing out his discussion on the management of metastatic triple-negative breast cancer, Aditya Bardia, MD, MPH, considers future treatment strategies that may improve outcomes for patients.

First-Line Treatment for Metastatic TNBC: Pembrolizumab + Chemotherapy

September 19th 2022

Comprehensive insight on use of first-line pembrolizumab plus chemotherapy in patients diagnosed with metastatic TNBC based on results from the KEYNOTE-355 trial.

Patient Scenario: A 44-Year-Old Woman With Metastatic TNBC

September 13th 2022

Centering discussion on a patient scenario of metastatic TNBC, Aditya Bardia, MD, MPH, highlights the value of first-line chemoimmunotherapy as a treatment option.

A Brief Overview of Treatment Options for Triple-Negative Breast Cancer

September 13th 2022

Expert oncologist Aditya Bardia, MD, MPH, shares his perspective on mainstay treatment options for patients diagnosed with metastatic triple-negative breast cancer.

Promising Strategies for Assessing Risk and Detecting Recurrence Earlier

August 31st 2022

Dr. Bardia discusses promising biomarkers and strategies for helping assess risk and detect recurrence in breast cancer.

Technical and Logistical Challenges Concerning the use of ctDNA Monitoring

August 31st 2022

Experienced clinician shares insight on potential challenges in the use of ctDNA monitoring.

Practical Clinical Applications for ctDNA Assessment

August 31st 2022

Clinical pearls addressing the current and potential future applications of ctDNA in breast cancer monitoring strategies.

Data Review: ctDNA Monitoring in Patients with Breast Cancer

August 31st 2022

Dr. Bardia reviews data from the ASCO 2022 Annual Meeting, focusing on serial postoperative ctDNA monitoring for breast cancer recurrence.

Clinical Evidence Supporting the use of ctDNA to Detect Recurrence

August 31st 2022

A breast cancer expert provides a brief overview of clinical evidence supporting the use of ctDNA to detect recurrence.

Best Practices for Assessing Risk of Recurrence in Patients with Breast Cancer

August 31st 2022

Aditya Bardia, MD, MPH shares his approach to assessing breast cancer recurrence risk and monitoring patients during and after treatment.